A dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of OSI-930 and erlotinib (E) in patients (pts) with advanced solid tumors

被引：0
|
作者：
Macpherson, I. [1 ,2 ,3 ]
Stewart, K. [1 ,2 ,3 ]
Chick, J. [1 ,2 ,3 ]
Brock, K. [1 ,2 ,3 ]
Poondru, S. [1 ,2 ,3 ]
Gedrich, R. [1 ,2 ,3 ]
Stephens, A. W. [1 ,2 ,3 ]
Evans, T. R. [1 ,2 ,3 ]
机构：
[1] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] OSI Pharmaceut, Oxford, England
[3] OSI Pharmaceut, Boulder, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3550
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors
    George, S.
    Lal, R.
    Camidge, D. R.
    Arkenau, H.
    Chick, J.
    Poondru, S.
    Yap, T. A.
    Eckhardt, S. G.
    Demetri, G. D.
    Scurr, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] A phase I, dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930, an oral tyrosine kinase inhibitor (TKI), in patients (pts) with advanced solid tumors
    Lal, R.
    Camidge, D. R.
    George, S.
    Demetri, G. D.
    Eckhardt, S. G.
    Stephens, A.
    Chick, J.
    Boinpally, R.
    Kaye, S. B.
    Scurr, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours
    Macpherson, I. R.
    Poondru, S.
    Simon, G. R.
    Gedrich, R.
    Brock, K.
    Hopkins, C. A.
    Stewart, K.
    Stephens, A.
    Evans, T. R. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (04) : 782 - 789
  • [4] A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies
    Chia, S.
    Chi, K.
    Kollmannsberger, C.
    Paton, K.
    Bhagat, K.
    D'Aloisi, S.
    Das-Gupta, A.
    Kletzl, H.
    Zwanziger, E.
    Gelmon, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 109 - 109
  • [5] A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies
    Chia, S. K.
    Chi, K. N.
    Kollmannsberger, C.
    Paton, K.
    Bhagat, K.
    D'Aloisio, S.
    Das-Gupta, A.
    Kletzl, H.
    Zwanziger, E.
    Gelmon, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Dose escalation and pharmacokinetic (pk) study of E 7389, a microtubule-hinding drug in patients (pts) with advanced solid tumors.
    Desai, KK
    Goel, S
    Mita, A
    Silberman, S
    Sicam, J
    Woeppel, S
    Macapinlac, M
    Berg, K
    Rowinski, E
    Mani, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 214S - 214S
  • [7] Pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of docetaxel (Doc) and oxaliplatin (Ox) in patients (Pts) with advanced solid tumors
    Zamboni, W.
    hwang, J. J.
    Strychor, S.
    Sidone, B. J.
    Zamboni, B. A.
    Malik, S. M.
    Catley, K.
    Grafton, K.
    Marshall, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors.
    Gangadhar, Tara C.
    Beumer, Jan Hendrik
    Espinoza-Delgado, Igor
    Anyang, Bean N.
    Karovic, Sanja
    Sharma, Manish
    Wen, Yujia
    Janisch, Linda A.
    Kindler, Hedy Lee
    Nanda, Rita
    Karrison, Theodore
    Ratain, Mark J.
    Maitland, Michael L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [10] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K. Padda
    Yelena Krupitskaya
    Laveena Chhatwani
    George A. Fisher
    Alexander D. Colevas
    Melanie San Pedro-Salcedo
    Rodney Decker
    Jane E. Latz
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
12345